Company Monitoring Page for CRISPR-Therapeutics

RT @BiomedicalRX: $CRSP likely no one has missed this news at this point! Congratulations CRISPR Therapeutics! Great news for patients a…

RT @Biotech2k1: t.co/6hsPiQca32 BOSTON & ZUG, Switzerland, June 08, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C…

RT @editcrisper: Caribou Biosciences Hits Clinical Runway with CRISPR-based Cancer Therapeutics $CRBU t.co/NyuVqPYxri

RT @GENbio: Force of Nature: Caribou Biosciences Hits Clinical Runway with #CRISPR based #Cancer Therapeutics Rachel Haurwitz, PhD, discus…

🚀The must-watch ticker today: CRISPR Therapeutics $CRSP -0.30% #AInvest_Magic #trading #investor #trade… t.co/9mNSCgTzuL

$CRSP likely no one has missed this news at this point! Congratulations CRISPR Therapeutics! Great news for pati… t.co/EIKyu0FTlF

RT @Biotech2k1: t.co/6hsPiQca32 BOSTON & ZUG, Switzerland, June 08, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C…

RT @Biotech2k1: t.co/6hsPiQca32 BOSTON & ZUG, Switzerland, June 08, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C…

RT @Biotech2k1: t.co/6hsPiQca32 BOSTON & ZUG, Switzerland, June 08, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C…

t.co/6hsPiQca32 BOSTON & ZUG, Switzerland, June 08, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRT… t.co/guJ801nrNe

RT @GrinsteinJ: While the initial data from @CaribouBio on their first-line, off-the-shelf, CRISPR-based cancer immunotherapies are promisi…

Force of Nature: Caribou Biosciences Hits Clinical Runway with CRISPR-based Cancer Therapeutics | @CaribouBio… t.co/oopV9PB7U7

Force of Nature: Caribou Biosciences Hits Clinical Runway with CRISPR-based Cancer Therapeutics | @CaribouBio… t.co/mKLM7JpcFM

Force of Nature: Caribou Biosciences Hits Clinical Runway with #CRISPR based #Cancer Therapeutics Rachel Haurwitz,… t.co/uPZtbLlKBm

Tune Therapeutics is developing a CRISPR-based platform, called TEMPO, that targets these epigenetic marks to contr… t.co/4u9pU0tRRh

RT @GrinsteinJ: While the initial data from @CaribouBio on their first-line, off-the-shelf, CRISPR-based cancer immunotherapies are promisi…

Force of Nature: Caribou Biosciences Hits Clinical Runway with CRISPR-based Cancer Therapeutics t.co/D6m8KgWNZi via @GENbio

Caribou Biosciences Hits Clinical Runway with CRISPR-based Cancer Therapeutics t.co/g3jpKGOyk5

Caribou Biosciences Hits Clinical Runway with CRISPR-based Cancer Therapeutics $CRBU t.co/NyuVqPYxri

t.co/iu6M8ApC5a $xdna $labu $labd $arkg $mrna $vrtx $alny $bntx $srpt $grph $crsp $rna $ntra $ions $ntla… t.co/8R3xuzcDhP

CRISPR Therapeutics (CRSP: $61.94) down 4.1% in 2 days; -84c [-1.3%]

RT @GrinsteinJ: While the initial data from @CaribouBio on their first-line, off-the-shelf, CRISPR-based cancer immunotherapies are promisi…

RT @AndrewE_Dunn: Scoop: Mammoth, the Doudna-founded CRISPR startup valued at $1 billion, is backing off diagnostics research after laying…

RT @GrinsteinJ: While the initial data from @CaribouBio on their first-line, off-the-shelf, CRISPR-based cancer immunotherapies are promisi…

RT @GrinsteinJ: While the initial data from @CaribouBio on their first-line, off-the-shelf, CRISPR-based cancer immunotherapies are promisi…

RT @GENbio: Force of Nature: Caribou Biosciences Hits Clinical Runway with #CRISPR based #Cancer Therapeutics Rachel Haurwitz, PhD, discus…

Force of Nature: Caribou Biosciences Hits Clinical Runway with #CRISPR based #Cancer Therapeutics Rachel Haurwitz,… t.co/62Myfr7lFf

RT @GrinsteinJ: While the initial data from @CaribouBio on their first-line, off-the-shelf, CRISPR-based cancer immunotherapies are promisi…

While the initial data from @CaribouBio on their first-line, off-the-shelf, CRISPR-based cancer immunotherapies are… t.co/xItyjYFJfA

CRISPR Therapeutics (CRSP: $61.78) drops to one-month low on robust volume; -$2.80 [-4.3%] Vol Index 1.5 [1 is avg]